Cadila Healthcare’s healthy product pipeline adds to earnings visibility2 min read 04 Jan 2022, 11:32 AM IST
As the extraordinary gains from covid treatment drug sales during the June quarter softened, the high base in the domestic market added to the muted near-term growth expectations
Cadila Healthcare Ltd has seen its stock prices correct more than 30% from highs seen in May’21. The muted near term growth expectations have kept investor sentiments under check.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started
Select your Category